These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24631871)

  • 1. Status of prophylactic and therapeutic genital herpes vaccines.
    Awasthi S; Friedman HM
    Curr Opin Virol; 2014 Jun; 6():6-12. PubMed ID: 24631871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status and prospects for development of an HSV vaccine.
    Johnston C; Koelle DM; Wald A
    Vaccine; 2014 Mar; 32(14):1553-60. PubMed ID: 24016811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine.
    Kuo T; Wang C; Badakhshan T; Chilukuri S; BenMohamed L
    Vaccine; 2014 Nov; 32(50):6733-45. PubMed ID: 25446827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes.
    Bernstein DI; Cardin RD; Bravo FJ; Hamouda T; Pullum DA; Cohen G; Bitko V; Fattom A
    Vaccine; 2019 Oct; 37(43):6470-6477. PubMed ID: 31515143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A paradigm shift: vaccine-induced antibodies as an immune correlate of protection against herpes simplex virus type 1 genital herpes.
    Awasthi S; Friedman HM
    J Infect Dis; 2014 Mar; 209(6):813-5. PubMed ID: 24285847
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
    Stanberry LR
    Herpes; 2004 Aug; 11 Suppl 3():161A-169A. PubMed ID: 15319086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines to prevent genital herpes.
    Egan K; Hook LM; LaTourette P; Desmond A; Awasthi S; Friedman HM
    Transl Res; 2020 Jun; 220():138-152. PubMed ID: 32272093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.
    Bernstein DI; Pullum DA; Cardin RD; Bravo FJ; Dixon DA; Kousoulas KG
    Vaccine; 2019 Jan; 37(1):61-68. PubMed ID: 30471955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine value profile for herpes simplex virus.
    Johnston C; Scheele S; Bachmann L; Boily MC; Chaiyakunapruk N; Deal C; Delany-Moretlwe S; Lee S; Looker K; Marshall C; Mello MB; Ndowa F; Gottlieb S
    Vaccine; 2024 Jul; 42(19S1):S82-S100. PubMed ID: 39003018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.
    Hoshino Y; Dalai SK; Wang K; Pesnicak L; Lau TY; Knipe DM; Cohen JI; Straus SE
    J Virol; 2005 Jan; 79(1):410-8. PubMed ID: 15596834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig.
    Bernstein DI; Earwood JD; Bravo FJ; Cohen GH; Eisenberg RJ; Clark JR; Fairman J; Cardin RD
    Vaccine; 2011 Mar; 29(11):2071-8. PubMed ID: 21238569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.
    Önnheim K; Ekblad M; Görander S; Bergström T; Liljeqvist JÅ
    Viruses; 2016 Apr; 8(4):110. PubMed ID: 27110813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current thinking on genital herpes.
    Hofstetter AM; Rosenthal SL; Stanberry LR
    Curr Opin Infect Dis; 2014 Feb; 27(1):75-83. PubMed ID: 24335720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.
    Ferenczy MW
    Curr Pharm Des; 2007; 13(19):1975-88. PubMed ID: 17627531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
    Stanberry LR; Spruance SL; Cunningham AL; Bernstein DI; Mindel A; Sacks S; Tyring S; Aoki FY; Slaoui M; Denis M; Vandepapeliere P; Dubin G;
    N Engl J Med; 2002 Nov; 347(21):1652-61. PubMed ID: 12444179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
    Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
    PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.
    Schiffer JT; Gottlieb SL
    Vaccine; 2019 Nov; 37(50):7363-7371. PubMed ID: 28958807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of rational vaccine designs for genital herpes immunotherapy.
    Kaufmann JK; Flechtner JB
    Curr Opin Virol; 2016 Apr; 17():80-86. PubMed ID: 26896782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender-specific predictors of genital herpes vaccine acceptance in a college population.
    Auslander BA; Rosenthal SL; Succop PA; Mills LM; Stanberry LR; Bernstein DI
    Int J STD AIDS; 2005 Jan; 16(1):27-30. PubMed ID: 15705269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.